The Blue Meanie trip lasts from 4-8 hours, with multiple peaks and a strong uplifting and psychoactive high. Users experience a heavy body buzz combined with rushes of euphoria, intense auditory and visual hallucinations. Good times!
Blue Meanies refer to a specific member of the Panaeolus Cyanascens species, also recognized as Copelandia Cyanescens. Blue Meanies mushrooms show blue bruising which is a sign of high potency.
These potent magic mushrooms are not to be confused with another Blue Meanie of the Psilocybe Cubensis family, as the Panaeolus Cyanascens species are known for containing upwards of twice the strength of regular cubensis strains. Blue Meanies are one of many mushrooms strains that contain tryptamine alkaloids, giving it more of a mind-boggling and psychedelic high due to the extreme levels of both psilocybin and psilocin alkaloids. This particular species originated in Asia and has spread to the sub-tropical forests of New Guinea and Mexico.
Psychedelic mushrooms have a longstanding, profound, and storied background among the many cultures that have historically used them. Today, the benefits of these powerful little fungi are being recognized in a big way. Currently, studies into the vast and multifarious use of psychoactive mushrooms are being conducted across the United States and abroad. One such study, published in the Journal of Psychopharmacology, found that, “a single dose of psilocybin produced substantial and enduring decreases in depressed mood and anxiety along with increases in quality of life.
Additionally, the mystical and profound experiences that so many have experienced since psilocybin entered the American psychedelic lexicon in the 1960s, are now beginning to be tested and explored in mainstream medical science. The results are promising and compelling, and paint a substantiated, positive, symbiotic picture of mushrooms as a powerful healer.
Specifically, clinical trials have been, and are currently, being conducted in the United States and abroad which involve patients dealing with life-threatening cancer. These trials mainly seek to understand the efficacy of high dose psilocybin, administered in therapeutic environments, as a tool for reducing the psychological stress and anxiety that often accompanies a life-threatening diagnosis.
The results so far have been promising. Under double-blind conditions, not only has a single, high-dose of psilocybin been shown to reduce symptoms of psychological distress among the terminal patient groups; the effects have been substantial and enduring.
Additionally, there is a growing body of research which suggests that part of why psilocybin is so effective is that it impacts neuroplasticity. That is, the brain’s ability to learn and grow and change.